Tanima De1, Honghong Zhang1, Cristina Alarcon1, Bianca Lec1, Juan Avitia1, Erin Smithberger2, Chuyu Chen1, Minnie Horvath1, Sara Kwan3, Mary Young3, Sarbani Adhikari3, John Kwon2, Jennifer Pacheco1, Gail Jarvik4, Wei-Qi Wei5, Frank Mentch6, Hakon Hakonarson6,7, Patrick Sleiman6,7, Adam Gordon1, John Harley8,9, Jim Linneman10, Scott Hebbring11, Loukia Parisiadou1, Minoli A Perera1. 1. Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 2. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina. 3. Department of Medicine, University of Chicago, Chicago, Illinois. 4. Departments of Medicine (Medical Genetics) and Genome Sciences, Universtiy of Washington Medical Center, Seattle, Washington. 5. Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. 6. The Center for Applied Genomics, The Children's Hospital of Philadelphia. 7. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 8. Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati. 9. US Department of Veterans Affairs Medical Center, Cincinnati, Ohio. 10. Office of Research Computing and Analytics, Marshfield Clinic Research Institute. 11. Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Abstract
OBJECTIVES: Primary nonresponse (PNR) to antitumor necrosis factor-α (TNFα) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR. PATIENTS AND METHODS: Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and associations were replicated in an independent cohort of 293 patients. Effect of the associated variant on gene expression and TNFα secretion was assessed by cell-based assays. Pleiotropic effects were investigated by Phenome-wide association study (PheWAS). RESULTS: We identified rs34767465 as associated with PNR to anti-TNFα therapy (odds ratio: 2.07, 95% CI, 1.46-2.94, P = 2.43 × 10-7, [replication odds ratio: 1.8, 95% CI, 1.04-3.16, P = 0.03]). rs34767465 is a multiple-tissue expression quantitative trait loci for FAM114A2. Using RNA-sequencing and protein quantification from HapMap lymphoblastoid cell lines (LCLs), we found a significant decrease in FAM114A2 mRNA and protein expression in both heterozygous and homozygous genotypes when compared to wild type LCLs. TNFα secretion was significantly higher in THP-1 cells [differentiated into macrophages] with FAM114A2 knockdown versus controls. Immunoblotting experiments showed that depletion of FAM114A2 impaired autophagy-related pathway genes suggesting autophagy-mediated TNFα secretion as a potential mechanism. PheWAS showed rs34767465 was associated with comorbid conditions found in IBD patients (derangement of joints [P = 3.7 × 10-4], pigmentary iris degeneration [P = 5.9 × 10-4], diverticulum of esophagus [P = 7 × 10-4]). CONCLUSIONS: We identified a variant rs34767465 associated with PNR to anti-TNFα biologics, which increases TNFα secretion through mechanism related to autophagy. rs34767465 may also explain the comorbidities associated with IBD.
OBJECTIVES: Primary nonresponse (PNR) to antitumor necrosis factor-α (TNFα) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR. PATIENTS AND METHODS: Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and associations were replicated in an independent cohort of 293 patients. Effect of the associated variant on gene expression and TNFα secretion was assessed by cell-based assays. Pleiotropic effects were investigated by Phenome-wide association study (PheWAS). RESULTS: We identified rs34767465 as associated with PNR to anti-TNFα therapy (odds ratio: 2.07, 95% CI, 1.46-2.94, P = 2.43 × 10-7, [replication odds ratio: 1.8, 95% CI, 1.04-3.16, P = 0.03]). rs34767465 is a multiple-tissue expression quantitative trait loci for FAM114A2. Using RNA-sequencing and protein quantification from HapMap lymphoblastoid cell lines (LCLs), we found a significant decrease in FAM114A2 mRNA and protein expression in both heterozygous and homozygous genotypes when compared to wild type LCLs. TNFα secretion was significantly higher in THP-1 cells [differentiated into macrophages] with FAM114A2 knockdown versus controls. Immunoblotting experiments showed that depletion of FAM114A2 impaired autophagy-related pathway genes suggesting autophagy-mediated TNFα secretion as a potential mechanism. PheWAS showed rs34767465 was associated with comorbid conditions found in IBD patients (derangement of joints [P = 3.7 × 10-4], pigmentary iris degeneration [P = 5.9 × 10-4], diverticulum of esophagus [P = 7 × 10-4]). CONCLUSIONS: We identified a variant rs34767465 associated with PNR to anti-TNFα biologics, which increases TNFα secretion through mechanism related to autophagy. rs34767465 may also explain the comorbidities associated with IBD.
Authors: Jeffrey S Hyams; Sonia Davis Thomas; Nathan Gotman; Yael Haberman; Rebekah Karns; Melanie Schirmer; Angela Mo; David R Mack; Brendan Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James Markowitz; Susan S Baker; Joel Rosh; Robert N Baldassano; Ashish Patel; Marian Pfefferkorn; Anthony Otley; Melvin Heyman; Joshua Noe; Maria Oliva-Hemker; Paul A Rufo; Jennifer Strople; David Ziring; Stephen L Guthery; Boris Sudel; Keith Benkov; Prateek Wali; Dedrick Moulton; Jonathan Evans; Michael D Kappelman; M Alison Marquis; Francisco A Sylvester; Margaret H Collins; Suresh Venkateswaran; Marla Dubinsky; Vin Tangpricha; Krista L Spada; Bradley Saul; Jessie Wang; Jose Serrano; Kevin Hommel; Urko M Marigorta; Greg Gibson; Ramnik J Xavier; Subra Kugathasan; Thomas Walters; Lee A Denson Journal: Lancet Date: 2019-03-29 Impact factor: 79.321
Authors: H Bar-Yoseph; N Levhar; L Selinger; U Manor; M Yavzori; O Picard; E Fudim; U Kopylov; R Eliakim; S Ben-Horin; Y Chowers; B Ungar Journal: Aliment Pharmacol Ther Date: 2017-11-09 Impact factor: 8.171
Authors: Chinyu Su; Bruce A Salzberg; James D Lewis; Julius J Deren; Asher Kornbluth; David A Katzka; Robert B Stein; Douglas R Adler; Gary R Lichtenstein Journal: Am J Gastroenterol Date: 2002-10 Impact factor: 10.864
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Andrea Santeford; Luke A Wiley; Sunmin Park; Sonya Bamba; Rei Nakamura; Abdelaziz Gdoura; Thomas A Ferguson; P Kumar Rao; Jun-Lin Guan; Tatsuya Saitoh; Shizuo Akira; Ramnik Xavier; Herbert W Virgin; Rajendra S Apte Journal: Autophagy Date: 2016-07-27 Impact factor: 16.016
Authors: Kristin E Burke; Hamed Khalili; John J Garber; Talin Haritunians; Dermot P B McGovern; Ramnik J Xavier; Ashwin N Ananthakrishnan Journal: Inflamm Bowel Dis Date: 2018-07-12 Impact factor: 5.325
Authors: E Louis; Z El Ghoul; S Vermeire; S Dall'Ozzo; P Rutgeerts; G Paintaud; J Belaiche; M De Vos; A Van Gossum; J-F Colombel; H Watier Journal: Aliment Pharmacol Ther Date: 2004-03-01 Impact factor: 8.171
Authors: Joshua C Denny; Lisa Bastarache; Marylyn D Ritchie; Robert J Carroll; Raquel Zink; Jonathan D Mosley; Julie R Field; Jill M Pulley; Andrea H Ramirez; Erica Bowton; Melissa A Basford; David S Carrell; Peggy L Peissig; Abel N Kho; Jennifer A Pacheco; Luke V Rasmussen; David R Crosslin; Paul K Crane; Jyotishman Pathak; Suzette J Bielinski; Sarah A Pendergrass; Hua Xu; Lucia A Hindorff; Rongling Li; Teri A Manolio; Christopher G Chute; Rex L Chisholm; Eric B Larson; Gail P Jarvik; Murray H Brilliant; Catherine A McCarty; Iftikhar J Kullo; Jonathan L Haines; Dana C Crawford; Daniel R Masys; Dan M Roden Journal: Nat Biotechnol Date: 2013-12 Impact factor: 54.908
Authors: Ian B Stanaway; Taryn O Hall; Elisabeth A Rosenthal; Melody Palmer; Vivek Naranbhai; Rachel Knevel; Bahram Namjou-Khales; Robert J Carroll; Krzysztof Kiryluk; Adam S Gordon; Jodell Linder; Kayla Marie Howell; Brandy M Mapes; Frederick T J Lin; Yoonjung Yoonie Joo; M Geoffrey Hayes; Ali G Gharavi; Sarah A Pendergrass; Marylyn D Ritchie; Mariza de Andrade; Damien C Croteau-Chonka; Soumya Raychaudhuri; Scott T Weiss; Matt Lebo; Sami S Amr; David Carrell; Eric B Larson; Christopher G Chute; Laura Jarmila Rasmussen-Torvik; Megan J Roy-Puckelwartz; Patrick Sleiman; Hakon Hakonarson; Rongling Li; Elizabeth W Karlson; Josh F Peterson; Iftikhar J Kullo; Rex Chisholm; Joshua Charles Denny; Gail P Jarvik; David R Crosslin Journal: Genet Epidemiol Date: 2018-10-08 Impact factor: 2.135